Abstract:Simple Summary Malignant peripheral nerve sheath tumours (MPNSTs) are highly aggressive and invasive peripheral soft-tissue sarcomas that typically develop in the context of neurofibromatosis type 1 (NF1). Compared with sporadic MPNSTs, patients with NF1-derived MPNSTs are younger and have a worse prognosis. The aim of our study is to further identify potential targets for the treatment of NF1-derived MPNSTs based on existing therapies. We found that the nuclear receptor corepressor 2 (NCOR2) could regulate ERK activation through the brain-derived neurotrophic factor (BDNF)/TrkB pathway, thereby affecting the growth of NF1-derived MPNSTs. This finding may provide new drug targets and combined drug therapy strategies for the clinical treatment of NF1-derived MPNSTs. (1) Background: malignant peripheral nerve sheath tumours (MPNSTs) are aggressive Schwann cell-derived sarcomas with dismal prognoses. Previous studies have shown that nuclear receptor corepressor 2 (NCOR2) plays a vital role in neurodevelopment and in various tumours. However, the impact of NCOR2 on the progression of MPNST remains unclear. (2) Methods: by GEO database, MPNST tissue microarray, and NF1-related tumour tissues and cell lines were used to explore NCOR2 expression level in the MPNSTs. The role and mechanism of NCOR2 in NF1-derived MPNSTs were explored by experiments in vivo and in vitro and by transcriptome high-throughput sequencing. (3) Results: NCOR2 expression is significantly elevated in NF1-derived MPNSTs and is associated with patient 10-year survival time. Knockdown of NCOR2 suppressed NF1-derived MPNST cell proliferation by blocking the cell cycle in the G0/G1 phase. Moreover, decreased NCOR2 expression could down-regulate MAPK signal activity through the BDNF/TrkB pathway. (4) Conclusions: our findings demonstrated that NCOR2 expression is significantly elevated in NF1-derived MPNSTs. NCOR2 knockdown can inhibit NF1-derived MPNST cell proliferation by weakened BDNF/TrkB/ERK signalling. Targeting NF1-derived MPNSTs with TrkB inhibitors, or in combination with ERK inhibitors, may be a novel therapeutic strategy for clinical trials.

Activation of the neuregulin-1/ErbB signaling pathway promotes the proliferation of neoplastic Schwann cells in human malignant peripheral nerve sheath tumors

CXCR4/CXCL12 Mediate Autocrine Cell- Cycle Progression in NF1-Associated Malignant Peripheral Nerve Sheath Tumors

ERBB2 and ERBB3 Growth Factor Receptors, Neuregulin-1, CD44 and Ki-67 Proliferation Index in Neurofibromatosis Type 1-associated Peripheral Nerve Sheath Tumors

PTEN and NF1 inactivation in Schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progression of peripheral nerve sheath tumors.

Spatial gene expression profiling unveils immuno-oncogenic programs of NF1-associated peripheral nerve sheath tumor progression

FOXM1 Promotes Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumor Progression in a NUF2 -Dependent Manner

Knockdown of NCOR2 Inhibits Cell Proliferation via BDNF/TrkB/ERK in NF1-Derived MPNSTs

Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.

Knockdown of HMGA2 Regulates the Level of Autophagy Via Interactions Between MSI2 and Beclin1 to Inhibit NF1-associated Malignant Peripheral Nerve Sheath Tumour Growth

Genomic And Molecular Characterization Of Malignant Peripheral Nerve Sheath Tumor Identifies The Igf1r Pathway As A Primary Target For Treatment (Publication With Expression Of Concern. See Vol. 25, Pg. 3195, 2019)

Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK

P01.23 * NEUROTENSIN PROMOTES THE PROGRESSION OF MALIGNANT GLIOMA THROUGH NTSR1 AND IMPACTS THE PROGNOSIS OF GLIOMA PATIENTS

mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition

Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors

Preclinical Therapeutic Efficacy of a Novel Pharmacologic Inducer of Apoptosis in Malignant Peripheral Nerve Sheath Tumors.

MicroRNA-204 critically regulates carcinogenesis in malignant peripheral nerve sheath tumors.

Protein Tyrosine Phosphatase Receptor S Acts as a Metastatic Suppressor in Malignant Peripheral Nerve Sheath Tumor via Profilin 1-Induced Epithelial-Mesenchymal Transition

Retraction Note: Genomic Amplification and High Expression of EGFR Are Key Targetable Oncogenic Events in Malignant Peripheral Nerve Sheath Tumor.

Cnsc-53. Shh Activation In Dedifferentiation During Tumor Progression In Mpnst

Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy

Dual Targeting of AKT and Mammalian Target of Rapamycin: a Potential Therapeutic Approach for Malignant Peripheral Nerve Sheath Tumor.